[3] DiMasi, J
doi: 10.3389/fphar.2024.1447097 Received 11 June 2024 Accepted 09 September 2024 Published 30 September 2024 Volume 15 - 2024 Edited by Fabrcio Souza Silva, Federal University of So Francisco Valley, Brazil Reviewed by Kevin Spelman, Health, Education and Research, United States Minhajur Rahman, University of Chittagong, Bangladesh Updates Copyright 2024 Moradi, Khazaei, Tarlan, Jasemi, Joshi, Aneva, Farzaei and Echeverra
Each addition increases complexity, cost, and potential for interactions or side effects
In a Novo Nordisk-funded study of semaglutide patients, about 4% of participants stopped taking the drug because of side effects